NeoGenomics' Patent Win Unlocks Path for Key Cancer Diagnostic Test

FORT MYERS, FL – December 15, 2025 – A pivotal growth signal emerged from the high-stakes world of oncology diagnostics this week, as NeoGenomics announced a decisive victory in its long-running patent dispute with rival Natera. Natera's voluntary withdrawal of its appeal solidifies a lower court ruling that invalidated key patents, effectively removing a critical barrier for NeoGenomics and clearing the path for the full commercial launch of its next-generation cancer test, RaDaR ST. For investors and industry observers, the move is more than just a legal footnote; it's a powerful indicator of shifting momentum in a multi-billion-dollar market and a stark reminder of the precarious nature of intellectual property in precision medicine.

The market’s reaction was swift and unambiguous. Following the initial court ruling in August 2025, NeoGenomics' stock (NASDAQ: NEO) surged over 20%, a clear vote of confidence from investors who saw the legal clouds parting. That momentum has continued, with analysts from firms like Jefferies and Needham raising their price targets, citing the immense potential of the RaDaR platform as a long-term growth driver. This legal resolution transforms that potential into a more tangible and immediate opportunity.

A Cleared Runway for RaDaR ST

At the heart of this dispute is the burgeoning market for molecular residual disease (MRD) testing, a revolutionary approach to cancer care. MRD tests analyze a patient's blood for trace amounts of circulating tumor DNA (ctDNA), offering a highly sensitive method for detecting cancer that may remain after surgery or treatment. For NeoGenomics, the now-unimpeded launch of its RaDaR ST assay represents a cornerstone of its future growth strategy.

The RaDaR ST test is a personalized assay, meaning it uses whole exome sequencing of a patient's tumor to create a unique genetic signature, which is then used to track for recurrence with exceptional sensitivity. The applications are profound, ranging from identifying patients at high risk of relapse to monitoring therapeutic effectiveness in real-time. This technology has the potential to become a new standard of care, guiding clinical decisions and improving patient outcomes.

The commercial prize is substantial. The global MRD testing market, valued at over $2 billion in 2023, is projected to expand at a compound annual growth rate exceeding 11%, potentially reaching nearly $6 billion by the early 2030s. With Natera's legal challenge neutralized, NeoGenomics can now focus its full resources on capturing a significant share of this expanding pie. The company has slated a full U.S. clinical launch for the first quarter of 2026, a timeline that now seems secure.

“We are very pleased that Natera has voluntarily decided to end this litigation process,” said Tony Zook, CEO of NeoGenomics, in a statement. “While we were confident in our position, this latest development nonetheless allows us to focus our full attention on executing a robust clinical launch of RaDaR ST in the first quarter of next year.” This statement, while measured, underscores the operational freedom the company has gained.

The Anatomy of a Legal Victory

The foundation of NeoGenomics' victory was laid in August 2025, when the U.S. District Court for the Middle District of North Carolina granted its motion for summary judgment. The court invalidated Natera's asserted claims from two patents (U.S. Patent Nos. 11,519,035 and 11,530,454), dismissing Natera's case with prejudice.

The court’s reasoning cuts to the core of a contentious issue in U.S. patent law. It found that Natera's patents were invalid because they claimed ineligible subject matter. Specifically, the court determined the patents were directed at a natural phenomenon—the correlation between ctDNA and cancer—and that the methods described were merely a “logical combination” of “standard, well-known techniques.” In the court's view, the patents lacked the necessary “inventive concept” to transform a discovery of nature into a patent-eligible invention.

This ruling is a direct application of the two-step framework established by the Supreme Court in the landmark cases Mayo v. Prometheus and Alice Corp. v. CLS Bank. This framework has created a challenging environment for companies in the diagnostics space, making it difficult to protect innovations that are based on observing biological correlations. While Natera has maintained that it has a robust portfolio of over 500 other patents and has been historically aggressive in defending its IP, the withdrawal of this appeal marks a significant concession on this particular front.

Shifting Sands: The Unsettled World of Diagnostic Patents

The NeoGenomics-Natera saga serves as a high-profile case study in the ongoing uncertainty surrounding patent eligibility in biotechnology. Since the Supreme Court’s Mayo decision in 2012, innovators have struggled to navigate a legal landscape where groundbreaking diagnostic methods can be deemed unpatentable for being too close to a “law of nature.”

Critics argue this precedent stifles innovation and disincentivizes investment in the diagnostics sector, as companies fear they cannot adequately protect their discoveries from imitation. The process of identifying a novel biomarker, developing a reliable test, and securing regulatory approval requires hundreds of millions of dollars, an investment that becomes riskier without strong patent protection. The invalidation of Natera’s patents on these grounds will send ripples across the industry, forcing other companies to re-evaluate the strength of their own patent portfolios and their strategies for protecting new technologies.

This legal environment is not static. A bipartisan bill, the Patent Eligibility Restoration Act (PERA), has been introduced in Congress with the aim of clarifying and potentially broadening the scope of what is considered patent-eligible. If passed, it could effectively overturn key aspects of the Mayo and Alice precedents, dramatically reshaping the strategic calculus for every company in the life sciences. Until then, however, legal battles like this one will continue to define the competitive boundaries in precision medicine.

From Courtroom to Clinic: The Patient Impact

Beyond the corporate balance sheets and legal arguments, the resolution of this case carries significant implications for cancer patients and the oncologists who treat them. The accelerated and unhindered rollout of advanced MRD tests like RaDaR ST promises to push cancer care further into the era of personalization.

For patients who have undergone treatment for cancers like breast or head and neck carcinoma—areas where RaDaR already has some Medicare coverage—these tests offer a new level of surveillance. Instead of waiting for symptoms or imaging to reveal a relapse, oncologists can use a simple blood test to detect molecular signs of recurrence months, or even years, earlier. This early warning can enable more timely and potentially more effective intervention.

Furthermore, MRD testing is becoming an invaluable tool in clinical trials for new cancer drugs. By using ctDNA levels as a surrogate endpoint, researchers can get an earlier readout on whether a therapy is working, potentially shortening drug development timelines and getting effective treatments to patients faster. As NeoGenomics moves forward with its RaDaR ST launch, it adds another powerful tool to the clinical arsenal, fueling a virtuous cycle where corporate competition ultimately accelerates advancements in patient care.